Yes — but only in a narrow sense. Digital brain games reliably improve the specific mental skills they drill in people with mild cognitive impairment, and the effect sizes in published trials are moderate and consistent. What they have not shown is the thing most readers actually want: proof that the training transfers to everyday abilities or slows the progression to dementia.
Mild cognitive impairment (MCI) is a measurable decline in memory or thinking that is greater than normal aging but not severe enough to interfere substantially with independent living. It is the stage where families start looking for something to do, and where the brain-training industry does most of its marketing. Understanding the gap between "scores went up" and "life got better" is the whole decision.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the trials actually measured
- The gains are concentrated, not general
- Does training prevent dementia?
- What the marketing is allowed to claim
- How to judge a program before you pay
- Frequently Asked Questions
What the trials actually measured
The strongest evidence comes from a meta-analysis by Hill and colleagues, published in the *American Journal of Psychiatry* in 2017, which pooled 17 randomized trials of computerized cognitive training in people with MCI. It found a moderate overall cognitive benefit, Hedges' g = 0.35 (95% CI 0.20–0.51), with no evidence of publication bias. Results held whether the comparison group did another activity or nothing at all, which rules out the simplest "they just enjoyed the attention" explanation. Two later analyses point the same direction with larger numbers.
A 2022 systematic review in the *Journal of Medical Internet Research* reported improved global cognition with a standardized mean difference of 0.54 (95% CI 0.35–0.73) and only moderate variation between studies. A newer meta-analysis limited to tablet- and computer-delivered programs found a global-cognition effect of g = 0.57, which matters practically: the benefit shows up on consumer hardware, not just lab equipment. In plain terms, a moderate effect means the average trained participant ends up scoring better than roughly two-thirds of untrained participants on the tests used. That is a real difference, and it is also a difference measured on tests, over weeks.
The gains are concentrated, not general
Hill's analysis broke the results down by ability, and the pattern is the clearest finding in this literature. Gains clustered in the skills the games actually train: working memory g = 0.74, nonverbal learning 0.50, attention 0.44, verbal memory 0.42, global cognition 0.38. The same analysis found no significant effect on executive function, processing speed, language, visuospatial skill — or instrumental activities of daily living, the category that covers managing medications, handling money, cooking and driving. That last one is the measure families care about most, and it did not move.
A 2026 meta-analysis took this question head-on by testing whether training generalizes. Near transfer — to similar untrained tasks — came out at g = 0.14 (95% CI −0.23 to 0.50) across 6 trials, and far transfer at g = 0.23 (95% CI −0.35 to 0.81) across 8. Both confidence intervals cross zero, meaning neither result can be distinguished from no effect, and both were graded very low certainty. Game scores improve more dependably than untrained real-world abilities do.
Does training prevent dementia?
No trial has shown that, and the reason is simpler than most people expect. The Cochrane review by Gates and colleagues on computerised cognitive training for preventing dementia in people with MCI concluded the evidence cannot establish whether such training prevents dementia or maintains cognition, rating the certainty low to very low — and noted that not one included trial measured dementia onset at all. Follow-up length is the other constraint.
The trials in Hill's analysis tracked participants for only one to three months. A 2026 paper in *JMIR Aging* notes that while short-term benefits are consistent, evidence on long-term effectiveness is "extremely limited". So the honest summary is that brain games are a reasonable adjunct to exercise, sleep, hearing correction, blood-pressure control and social activity — not a demonstrated way to stop progression.
What the marketing is allowed to claim
Regulators have already policed this ground once. The Federal Trade Commission announced on January 5, 2016 that Lumos Labs, maker of Lumosity, would pay $2 million to settle charges that it deceptively claimed its games improved performance at school, work and sports and delayed age-related cognitive decline. A $50 million judgment was suspended, and the company must base future health claims on "competent and reliable scientific evidence." No brain-training product is FDA-authorized for mild cognitive impairment.
Lumos Labs does have a cleared prescription product built from 13 Lumosity games, but it is indicated for adults aged 22 to 55 with inattentive or combined-type ADHD; EndeavorRx, the other well-known prescription game, was cleared for children with ADHD. A clearance for one condition and age band says nothing about MCI. If a product's page implies otherwise, that is a marketing claim, not a regulatory status.
How to judge a program before you pay
The trial evidence supports structured training as an activity, not any particular brand. Use these checks: Tell the treating clinician what you are using. MCI has reversible contributors — medication side effects, depression, thyroid disease, sleep apnea, untreated hearing loss — and a program that keeps someone busy can delay that workup.
- **Look for a named, specific claim.** "Improves working memory on the tasks trained" is defensible. "Delays cognitive decline" or "prevents dementia" is the claim the FTC acted on.
- **Check who the evidence was gathered in.** Studies in healthy young adults do not transfer to an MCI diagnosis.
- **Treat any FDA language skeptically.** Ask which condition and which age range the clearance covers.
- **Prefer month-to-month billing.** Benefits in trials were measured over one to three months; there is no evidence base supporting a multi-year prepaid commitment.
- **Watch for crowding out.** If the program replaces walking, choir, cards with friends or a hearing-aid appointment, it is a net loss.
Frequently Asked Questions
How long should someone train before deciding it's working?
Judge it on the one-to-three-month horizon the trials used, and judge it on whether the person engages with it, not on in-game scores. Rising game scores are the finding that transfers least.
Are free apps as good as paid subscriptions?
Nothing in the evidence base supports price as a quality marker. The reproducible effect in the tablet- and computer-based meta-analysis came from the structure of the training, not the hardware or the cost.
Is this better than crosswords, puzzles or card games?
No trial pits them against each other in MCI, so there is no evidence favoring commercial software over an engaging activity someone will keep doing.





